Retatrutide
Triple GLP-1 / GIP / glucagon agonist
Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon pathways. Early-phase studies show pronounced fat-loss and metabolic effects beyond single- or dual-agonist analogues.
- Typical dose
- 2–12 mg once weekly (titrated)
- Half-life
- ~6 days
- Administration
- Subcutaneous injection
- Research status
- Phase III clinical trials
What it is
Retatrutide is a next-generation incretin mimetic under investigation. Unlike semaglutide or tirzepatide, it is a triple agonist — activating GLP-1, GIP, and glucagon receptors. This tri-agonist profile enhances weight reduction through both appetite suppression and increased energy expenditure.
Why researchers use it
- Targets multiple pathways for superior weight-management outcomes
- Suppresses appetite while simultaneously elevating caloric burn
- May achieve greater body-weight reductions than GLP-1 or dual agonists
- Shows potential in obesity and related metabolic conditions
Dosing protocol (for research)
- Initial dose: 0.5 mg weekly
- Escalation: 1.0 → 2.0 → 4.0 mg weekly as tolerated
- Long half-life allows convenient once-weekly administration
Preparation & injection
- Reconstitute with bacteriostatic water per vial specifications
- Store refrigerated after mixing; use insulin syringes for accuracy
- Subcutaneous administration only; rotate sites to minimize irritation or lipodystrophy
Safety notes
- GI side effects (nausea, slowed digestion) are common in early use
- Potential elevated heart rate from glucagon receptor activation
- Monitor liver enzymes and cardiovascular health in research settings
Researcher tips
- Effective in cutting or fat-loss protocols alongside resistance training and high protein intake
- Can be stacked with L-carnitine or AOD-9604 for enhanced metabolic outcomes
- Hydration, electrolytes, and dietary fiber reduce GI distress during titration
Bonus: popular escalation protocol
Some protocols start at 2 mg weekly and increase by +1 mg each week until reaching 4 mg. The dose is held there until weight loss plateaus, at which point incremental +1 mg increases are introduced. If the plateau persists for 10+ days, dosage may be advanced further.
Reconstitution & concentration
Reconstitute with bacteriostatic water per vial specifications, store refrigerated, and use insulin syringes for accurate measurement. Long half-life supports once-weekly subQ dosing.
- Initial: 0.5 mg weekly
- Escalation: 1.0 → 2.0 → 4.0 mg weekly as tolerated
- Bonus escalation protocol: start 2 mg/week, +1 mg weekly to 4 mg; hold until plateau, then +1 mg further if plateau lasts 10+ days
Stacks
- Metabolic Accelerator Stack: Retatrutide 4–12 mg/week + SLU-PP-332 250–500 mcg daily, 12–16 weeks
- Appetite Overdrive Stack: Retatrutide 5–10 mg/week + Tesofensine 250–500 mcg daily, 8–12 weeks
- Double Hormone Synergy Stack: Cagri/Sema (start 0.25 mg each weekly) + Retatrutide 4–8 mg/week, 12–20 weeks
Researcher tips also note stacking with L-Carnitine or AOD-9604 for enhanced metabolic outcomes.